Thyroid Nodule Clinical Trial
— EfFECTSOfficial title:
Efficacy of [18F]-2-fluoro-2-deoxy-D-glucose Positron Emission Tomography (FDG-PET) in Evaluation of Cytological Indeterminate Thyroid Nodules Prior to Surgery: a Multicentre Cost-effectiveness Study
Verified date | February 2022 |
Source | Radboud University Medical Center |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The purpose of this study is to determine whether the use of molecular imaging using FDG-PET/CT could prevent unnecessary diagnostic thyroid surgery in case of indeterminate cytology during fine-needle aspiration biopsy.
Status | Completed |
Enrollment | 132 |
Est. completion date | February 15, 2022 |
Est. primary completion date | January 1, 2020 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: 1. Documented history of a solitary thyroid nodule or a dominant nodule within multinodular disease, with (US-guided) FNAC performed by a dedicated radiologist or experienced endocrinologist or pathologist, demonstrating an indeterminate cytological examination (i.e. Bethesda category III or IV) according to the local pathologist and confirmed after central review; 2. Scheduled for surgical excision (preferably) within 2 months of the inclusion date; 3. Age = 18 years; 4. Euthyroid state with a serum thyrotropin (TSH) or a free T4 level within the institutional upper and lower limits of normal, measured within 2 months of registration. In case of a suppressed TSH: a negative 123I, 131I or 99mTcO4- scintigraphy must be available ("cold nodule"); 5. In patients with multinodular disease and a dominant nodule, the nuclear medicine physician responsible for FDG-PET/CT scan interpretation must determine whether the nodule is likely to be discriminated on FDG-PET/CT imaging prior to enrolment; 6. Willing to participate in all aspects of the study; Exclusion Criteria: 1. High a priori probability of malignancy: - FNAC Bethesda category V or VI during local reading or central review; - Prior radiation exposure / radiotherapy to the thyroid; - Prior neck surgery or radiation that in the opinion of the PI has disrupted tissue architecture of the thyroid; - New unexplained hoarseness, change of voice, stridor or paralysis of a vocal cord; - In case a benign reason has been found (e.g. vocal cord edema), the patient is eligible; - Thyroid nodule discovered as a FDG-PET positive incidentaloma - New cervical lymphadenopathy highly suspicious for malignancy; - In case malignancy is excluded, patient is eligible; - Previous treatment for thyroid carcinoma or current diagnosis of any other malignancy that is known to metastasize to the thyroid; - Known metastases of thyroid carcinoma; - Known genetic predisposition for thyroid carcinoma: - Familiar Non-Medullary Thyroid Cancer (NMTC) - Familiar Papillary Thyroid Cancer (FPTC) - Familiar Adenomatoid Polyposis Coli syndrome (FAP, Gardner syndrome, APC-gene mutations on chromosome 5q21) - Morbus Cowden (PTEN mutation on chromosome 10q23.3) - PTC / nodular thyroid hyperplasia / papillary renal tumours. Linked to locus 1q21. 2. Proven benign disease or insufficient material for a cytological diagnosis: - FNAC Bethesda category I or II during local reading or central review 3. Performance of non-routine additional diagnostic tests that alter the patients treatment policy (e.g. mutation analysis on cytology) 4. Inability to undergo randomization: - Any patient that will receive thyroid surgery for other reasons (e.g. mechanical or cosmetic complaints). 5. Inability to undergo treatment: - Inability to undergo surgery in the opinion of the surgeon / anaesthetist. 6. Contra-indications for FDG-PET/CT: - Patient has evidence of infection localized to the neck in the 14 days prior to the FDG-PET/CT scan; - Inability to tolerate lying supine for the duration of an FDG-PET/CT examination (~10-15min); - Poorly regulated diabetes mellitus (see next item); - Hyperglycaemia at time of FDG injection prior to PET/CT (fasting serum glucose >200mg/dL [>11.1 mmol/L]); - The use of short-acting insulins within 4 hours of the PET scan is not allowed - If female and fertile: signs and symptoms of pregnancy or a positive pregnancy test / breast-feeding; - A formal negative pregnancy test is not obligatory - (severe) claustrophobia; - Low dose benzodiazepines are allowed 7. General contra-indications: - Inability to give informed consent; - Severe psychiatric disorder; |
Country | Name | City | State |
---|---|---|---|
Netherlands | MeanderMC | Amersfoort | Utrecht |
Netherlands | AMC | Amsterdam | Noord-Holland |
Netherlands | Onze Lieve Vrouwe Gasthuis | Amsterdam | |
Netherlands | VUmc | Amsterdam | Noord-Holland |
Netherlands | Rijnstate | Arnhem | |
Netherlands | Reinier de Graaf Ziekenhuis | Delft | |
Netherlands | UMCG | Groningen | |
Netherlands | LUMC | Leiden | Zuid-Holland |
Netherlands | MUMC | Maastricht | Limburg |
Netherlands | St. Antonius | Nieuwegein | |
Netherlands | Radboudumc | Nijmegen | Gelderland |
Netherlands | ErasmusMC | Rotterdam | Zuid-Holland |
Netherlands | HagaZiekenhuis | The Hague | |
Netherlands | UMCU | Utrecht | |
Netherlands | Isala Klinieken | Zwolle |
Lead Sponsor | Collaborator |
---|---|
Radboud University Medical Center | Dutch Cancer Society |
Netherlands,
de Geus-Oei LF, Pieters GF, Bonenkamp JJ, Mudde AH, Bleeker-Rovers CP, Corstens FH, Oyen WJ. 18F-FDG PET reduces unnecessary hemithyroidectomies for thyroid nodules with inconclusive cytologic results. J Nucl Med. 2006 May;47(5):770-5. — View Citation
de Koster EJ, de Geus-Oei LF, Brouwers AH, van Dam EWCM, Dijkhorst-Oei LT, van Engen-van Grunsven ACH, van den Hout WB, Klooker TK, Netea-Maier RT, Snel M, Oyen WJG, Vriens D; EfFECTS trial study group. [(18)F]FDG-PET/CT to prevent futile surgery in indet — View Citation
de Koster EJ, de Geus-Oei LF, Dekkers OM, van Engen-van Grunsven I, Hamming J, Corssmit EPM, Morreau H, Schepers A, Smit J, Oyen WJG, Vriens D. Diagnostic Utility of Molecular and Imaging Biomarkers in Cytological Indeterminate Thyroid Nodules. Endocr Rev. 2018 Apr 1;39(2):154-191. doi: 10.1210/er.2017-00133. Review. — View Citation
de Koster EJ, Noortman WA, Mostert JM, Booij J, Brouwer CB, de Keizer B, de Klerk JMH, Oyen WJG, van Velden FHP, de Geus-Oei LF, Vriens D; EfFECTS trial study group. Quantitative classification and radiomics of [(18)F]FDG-PET/CT in indeterminate thyroid n — View Citation
Vriens D, Adang EM, Netea-Maier RT, Smit JW, de Wilt JH, Oyen WJ, de Geus-Oei LF. Cost-effectiveness of FDG-PET/CT for cytologically indeterminate thyroid nodules: a decision analytic approach. J Clin Endocrinol Metab. 2014 Sep;99(9):3263-74. doi: 10.1210/jc.2013-3483. Epub 2014 May 29. — View Citation
Vriens D, de Wilt JH, van der Wilt GJ, Netea-Maier RT, Oyen WJ, de Geus-Oei LF. The role of [18F]-2-fluoro-2-deoxy-d-glucose-positron emission tomography in thyroid nodules with indeterminate fine-needle aspiration biopsy: systematic review and meta-analysis of the literature. Cancer. 2011 Oct 15;117(20):4582-94. doi: 10.1002/cncr.26085. Epub 2011 Mar 22. Review. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Fraction of unbeneficial treatment | Unbeneficial treatment is defined as either: surgery in benign disease watchful waiting in malignant disease benign or malignant disease is defined on final histology (after surgery) or 12 month follow-up including confirmatory neck ultrasonography. This parameter is compared between both study arms based on intention-to-treat. |
12 months after inclusion | |
Secondary | Fraction Complications | SO1b: To determine the effect of incorporation of FDG-PET/CT on the complication-ratio. | 12 months after inclusion | |
Secondary | Fraction False-Negative FDG-PET/CT's | SO1c: To determine the false-negative fraction of FDG-PET/CT in this population. | 12 months after inclusion | |
Secondary | Lesion and Patient Characteristics | SO1d: To determine the influence of lesion size, pathological classification and patient characteristics on the diagnostic accuracy of FDG-PET/CT. | 12 months after inclusion | |
Secondary | Fraction Incidental FDG-PET/CT Findings | SO1e: To determine whether incorporation of FDG-PET/CT of the head and neck lead to overdiagnosis in non-thyroidal incidental findings. | 12 months after inclusion | |
Secondary | Overall and Disease Free Survival | SO1f: To determine the short-term overall and disease free survival in both study arms. | 12 months after inclusion | |
Secondary | FDG-PET/CT Implementation-hampering Factors | SO1g: To determine which factors hamper implementation of this modality for this indication (structured interviews). | 12 months after inclusion | |
Secondary | Fraction of Patients being operated despite negative FDG-PET/CT | SO1h: To determine the fraction of patients that cannot be reassured by a negative PET-scan (experimental arm only) despite careful selection of patients (implementability). | 12 months after inclusion | |
Secondary | HRQoL-scores according to SF36-II, EQ-5D-5L, SF-HLQ and ThyPRO including changes | SO2a: To determine the impact on the experienced HRQoL between the group with and without FDG-PET/CT according to 4 different questionnaires at 4 timepoints during the first 12 months after FDG-PET/CT. SO2b: To determine whether patients in the experimental arm with negative PET-findings have a different HRQoL than those who receive surgery independent of the FDG-PET/CT results. |
Baseline, 2 months, 6 months and 12 months after inclusion | |
Secondary | Direct Costs | SO3a: To determine the effect of incorporation of FDG-PET/CT on the mean direct costs (=volume of care multiplied by activity based costs) per patient during the first 12 months after FDG-PET/CT. | 12 months after inclusion | |
Secondary | Number of Hospitalisation Days | SO3b: To determine the effect of incorporation of FDG-PET/CT on the average length of hospital stay for treatment of (complications of) thyroid lesions? | 12 months after inclusion | |
Secondary | Number of Sick Leave Days | SO3c: To determine the total number of sick leave days for the first three months in the patients? Do these differ between both study arms? | 3 months after inclusions | |
Secondary | incremental Net Monetary Benefit | SO3d: To determine the incremental Net Monetary Benefit of incorporation of FDG-PET/CT with respect to quality-adjusted life-years (QALYs, based on EQ-5D-5L index and overall survival) saved including sensitivity analysis. SO3e: To determine the incremental Net Monetary Benefit of incorporation of FDG-PET/CT with respect to decrease in unbeneficial treatment. Sensitivity analysis will be performed. A mere description will be given as there is no "accepted" value for this kind of analysis. |
12 months after inclusion | |
Secondary | Tissue Protein- and Gene-expression profile | SO4a: Are there potential protein- or gene-expression profiles, capable of determining the nature of the FNAC-indeterminate nodes (cytology) SO4b: What is the interaction/correlation between the parameters mentioned in SO4a and the results of the FDG-PET/CT scan and the final diagnosis? | 12 months after inclusion of last patient | |
Secondary | Molecular biomarkers in relation to FDG-PET/CT | SO4b: What is the interaction/correlation between the parameters mentioned in SO4a and the results of the FDG-PET/CT scan and the final diagnosis? Can these tissue molecular biomarkers help in selecting the patients that benefit most from FDG-PET, or vice versa? Can higher pre-operative diagnostic accuracy be achieved by combining FDG-PET and molecular biomarkers? Are molecular biomarkers related to false-positive or false-negative FDG-PET/CT results? |
12 months after inclusion of last patient |
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT04614389 -
Utility of Contrast-Enhanced Sonography and Shear Wave Elastography
|
N/A | |
Recruiting |
NCT03295955 -
Comparing Efficacy of Postoperative Oral Antibiotic Use in Trans-Oral Thyroidectomy
|
N/A | |
Completed |
NCT04647006 -
Comparison of TOETVA and Conventional Thyroidectomy
|
N/A | |
Not yet recruiting |
NCT06029946 -
B-mode Ultrasound, Sono-Elastography, and Diffusion-weighted Imaging MRI in Thyroid Nodules
|
||
Recruiting |
NCT05025046 -
NGS-based Thyroscan Genomic Classifier in the Diagnosis of Thyroid Nodules
|
||
Terminated |
NCT01320813 -
Trial Comparing Complication Rates Associated With Robot-assisted Thyroidectomy to External Thyroidectomy
|
N/A | |
Completed |
NCT00877630 -
Minimal Invasiveness of Endoscopic Thyroidectomy
|
N/A | |
Completed |
NCT01964508 -
microRNA in Thyroid Cancer
|
||
Completed |
NCT06306599 -
Ultrasound Operator Influence on Diagnostics With AI for Thyroid Nodules - Clinial Trial
|
N/A | |
Recruiting |
NCT04730726 -
In Vivo Multispectral Optoacoustic Imaging of Thyroid Nodules
|
N/A | |
Not yet recruiting |
NCT03884140 -
Clinical Diagnostic Approach for Cases of Thyroid Nodules
|
||
Completed |
NCT04277455 -
Effect of Ultrasound Guided Laser Ablation Therapy on Symptomatic Benign Thyroid Nodules
|
N/A | |
Recruiting |
NCT02225509 -
Clinical Validation of a Molecular Signature to Detect Cancer in Thyroid Nodules With Indeterminate Cytology
|
N/A | |
Completed |
NCT00552253 -
Levothyroxine Treatment in Thyroid Benign Nodular Goiter
|
N/A | |
Not yet recruiting |
NCT03700762 -
Application of Ultrasonic Gray-scale Ratio in Differentiating Benign From Malignant Thyroid Nodules.
|
||
Enrolling by invitation |
NCT01757834 -
Shear Wave Ultrasound Elastography in Noninvasive Diagnosis of Thyroid Nodules
|
N/A | |
Completed |
NCT01292044 -
The Role of Elastography in the Diagnosis of Thyroid Nodules
|
N/A | |
Completed |
NCT00858104 -
Percutaneous Laser Ablation in Benign Thyroid Nodules.Long Term Results
|
Phase 4 | |
Completed |
NCT00651625 -
Reciprocating Medical Devices - a Study of a New Safety Device
|
N/A | |
Completed |
NCT05132478 -
The Effect of Surgeon Emotional Support on Treatment Choice for Low-risk Thyroid Cancer
|
N/A |